Sanofi offers refunds for Cablivi in novel model for rebates
Pharmaceutical Technology
JANUARY 27, 2023
On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Before Cablivi’s approval, patients relied on a combination of plasma exchange plus corticosteroids and immunomodulators as the standard of care (SOC) for treatment.
130 
Let's personalize your content